ABA Therapy Business Valuations — Why PE Is Paying 5×–10× EBITDA

Applied Behavior Analysis (ABA) therapy businesses are among the highest-valued healthcare services companies in the M&A market right now — trading at 5× to 10× EBITDA, with the largest, most operationally mature platforms commanding multiples at or above the top of that range. Private equity firms including Blackstone-backed Behavioral Health Group (BHG), Centria Healthcare, Autism Learning Partners, and numerous regional PE groups have been aggressively acquiring ABA providers since 2020, and activity has not slowed meaningfully into 2026. If you own an ABA therapy practice and have been wondering whether now is the right time to explore a sale, the short answer is that the market for quality operators is as competitive as it has ever been.

 This article is for ABA therapy practice owners who are thinking about a full or partial sale, or simply want to understand what their practice is worth in the current market. The valuation dynamics in this space are genuinely unusual relative to most healthcare businesses, and understanding why helps you negotiate better.

How ABA Therapy Businesses Are Valued

ABA therapy practices are almost always valued on EBITDA — earnings before interest, taxes, depreciation, and amortization — rather than revenue or collections. A practice generating $3 million in revenue with 18% EBITDA margins has a $540,000 EBITDA base. At a 7× multiple, that's a $3.78 million enterprise value. A practice at the same revenue with 25% EBITDA margins has a $750,000 base — and at 8× that's $6 million. Margin management is the single most powerful lever an ABA owner can pull before going to market.

Current ABA Therapy Multiples in 2026

The 5×–10× EBITDA range reflects real transaction data. Smaller practices — under $1.5 million in EBITDA — typically trade at the lower end, particularly if they are founder-dependent or have significant staff turnover. Mid-market practices — $1.5 million to $4 million in EBITDA — with professional operations, multiple clinic locations or a hybrid model, and documented clinical quality metrics are consistently trading in the 7×–9× range. The largest platforms — $4 million+ EBITDA with geographic scale — have access to the top of the range. The key insight is that the multiple expansion happens fastest when you cross $2 million in EBITDA.

Who Is Buying ABA Therapy Businesses Right Now

The most active acquirers in 2026 are PE-backed platforms with existing ABA portfolios executing geographic roll-up strategies. Behavioral Health Group (BHG), Centria Healthcare, Autism Learning Partners, and Hopebridge are among the national platforms actively acquiring. Beyond them, several regional PE-backed ABA groups have raised capital specifically for Southeast and Mid-Atlantic expansion. Individual buyers with clinical backgrounds are rare above $2 million in revenue because the capital required exceeds what SBA financing typically covers for healthcare businesses.

What Makes an ABA Practice Worth More

The highest-valued ABA practices share a consistent profile: EBITDA margins of 20% or above; a diversified payer mix with commercial insurance comprising a meaningful share of revenue; a stable BCBA (Board Certified Behavior Analyst) supervision team with manageable turnover; strong clinical outcomes documentation; multiple revenue delivery channels (center-based and in-home or school-based); and a practice that is not dependent on the founding clinician for clinical oversight or business development. The practices that trade at 9× or 10× EBITDA are the ones where the founder can step back and the organization continues to perform.

What Hurts ABA Therapy Valuations

The most common valuation risks: heavy Medicaid concentration (above 60–70% is a flag for most PE buyers); high RBT turnover; a waitlist that is not being converted efficiently; founder dependency on clinical supervision; and billing compliance exposure, which is the number one legal risk in behavioral health M&A. Any billing irregularity that surfaces during diligence stops a PE deal immediately.

How Long Does It Take to Sell an ABA Business

ABA transactions with PE buyers typically run six to twelve months from engagement to close. Healthcare-specific diligence — clinical quality review, billing compliance audit, credentialing review, and insurance contract assignability analysis — adds time relative to a standard business sale. Planning for a 90-day diligence period after an LOI is signed is realistic; 120 days is not uncommon for larger transactions. The sellers who close in six months are the ones who have a clean billing record, current credentialing, and a data room ready before the first buyer call.

John's Take

ABA is one of the few sectors where I consistently tell owners: the multiple you can get today is genuinely exceptional relative to most healthcare businesses, and it reflects structural demand for autism services that isn't going away. But the valuation spread in this space is wider than almost any other industry I work in. I've seen two ABA practices at the same revenue trade at 5× and 9× EBITDA in the same quarter. The difference wasn't the market — it was margin, payer mix, and whether the clinical team was built to outlast the founder. If you're at 12% EBITDA margins right now, getting to 20% before you sell could double your proceeds. That's the kind of thing worth spending 18 months on.

ABA Therapy Transactions in the Southeast and Mid-Atlantic

The Southeast is among the highest-priority geographic targets for PE-backed ABA platforms right now — population growth, favorable reimbursement environments, and significant unmet demand in suburban and secondary markets make this region attractive to national acquirers.